James E. Flynn - 28 Dec 2022 Form 4 Insider Report for Oncorus, Inc.

Reporting relationship: Possible Member of 10% Group, 10%+ Owner
Issuer ticker: N/A
Reported as of: 28 Dec 2022
Net transaction value: -$88,254
SEC form: 4
Accepted by SEC: 30 Dec 2022, 18:16:31 UTC
Prior SEC filing: 27 Dec 2022
Next SEC filing: 11 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for Oncorus, Inc. on 30 Dec 2022.

Key facts

This page summarizes James E. Flynn's Form 4 filing for Oncorus, Inc..
9 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 Dec 2022, 18:16.

Change

Previous filing in this sequence was filed on 27 Dec 2022.
Current net transaction value: -$88,254.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONCR transaction

Common Stock

Sale

Transaction value: $6,189
Shares: -24,757
Change %: -1.9%
Price: $0.2500^*
Shares after: 1,281,242
Date: 28 Dec 2022
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F1, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $6,189
Shares: -24,757
Change %: -1.9%
Price: $0.2500^*
Shares after: 1,281,242
Date: 28 Dec 2022
Ownership: Through Deerfield Private Design Fund III, L.P.
Footnotes: F1, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $1,524
Shares: -6,096
Change %: -1.9%
Price: $0.2500^*
Shares after: 315,455
Date: 28 Dec 2022
Ownership: Through Deerfield Partners, L.P.
Footnotes: F1, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $16,408
Shares: -63,107
Change %: -4.9%
Price: $0.2600^*
Shares after: 1,218,135
Date: 29 Dec 2022
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F2, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $16,408
Shares: -63,108
Change %: -4.9%
Price: $0.2600^*
Shares after: 1,218,134
Date: 29 Dec 2022
Ownership: Through Deerfield Private Design Fund III, L.P.
Footnotes: F2, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $4,040
Shares: -15,538
Change %: -4.9%
Price: $0.2600^*
Shares after: 299,917
Date: 29 Dec 2022
Ownership: Through Deerfield Partners, L.P.
Footnotes: F2, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $16,693
Shares: -61,826
Change %: -5.1%
Price: $0.2700^*
Shares after: 1,156,309
Date: 30 Dec 2022
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F3, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $16,693
Shares: -61,826
Change %: -5.1%
Price: $0.2700^*
Shares after: 1,156,308
Date: 30 Dec 2022
Ownership: Through Deerfield Private Design Fund III, L.P.
Footnotes: F3, F4, F5

ONCR transaction

Common Stock

Sale

Transaction value: $4,109
Shares: -15,220
Change %: -5.1%
Price: $0.2700^*
Shares after: 284,697
Date: 30 Dec 2022
Ownership: Through Deerfield Partners, L.P.
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James E. Flynn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.25 to $0.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1-3 of this Form 4.

Footnote F2

The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.25 to $0.27, inclusive.

Footnote F3

The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.26 to $0.28, inclusive.

Footnote F4

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund III and Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

Footnote F5

In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.